Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The price of Iovance Biotherapeutics Inc (NASDAQ: IOVA) closed at $9.61 in the last session, up 3.89% from day before closing price of $9.25. In other words, the price has increased by $3.89 from its previous closing price. On the day, 3.87 million shares were traded. IOVA stock price reached its highest trading level at $9.75 during the session, while it also had its lowest trading level at $9.28.
Ratios:
We take a closer look at IOVA’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 4.85 and its Current Ratio is at 5.15. In the meantime, Its Debt-to-Equity ratio is 0.11 whereas as Long-Term Debt/Eq ratio is at 0.09.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Piper Sandler on July 29, 2024, Downgraded its rating to Neutral and sets its target price to $10 from $19 previously.
On November 20, 2023, Goldman started tracking the stock assigning a Buy rating and target price of $12.
Barclays reiterated its Overweight rating for the stock on September 18, 2023, while the target price for the stock was revised from $40 to $18.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Feb 20 ’24 when MCPEAK MERRILL A bought 250,000 shares for $9.15 per share. The transaction valued at 2,287,500 led to the insider holds 320,150 shares of the business.
Dukes Iain D. bought 32,000 shares of IOVA for $292,800 on Feb 20 ’24. The Director now owns 54,000 shares after completing the transaction at $9.15 per share. On Feb 20 ’24, another insider, Rothbaum Wayne P., who serves as the Director of the company, bought 5,000,000 shares for $9.15 each. As a result, the insider paid 45,750,000 and bolstered with 28,067,333 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IOVA now has a Market Capitalization of 2916769280 and an Enterprise Value of 2585911296. For the stock, the TTM Price-to-Sale (P/S) ratio is 89.01 while its Price-to-Book (P/B) ratio in mrq is 3.72. Its current Enterprise Value per Revenue stands at 78.906 whereas that against EBITDA is -5.887.
Stock Price History:
Over the past 52 weeks, IOVA has reached a high of $18.33, while it has fallen to a 52-week low of $3.21. The 50-Day Moving Average of the stock is -1.95%, while the 200-Day Moving Average is calculated to be -7.59%.
Shares Statistics:
According to the various share statistics, IOVA traded on average about 6.71M shares per day over the past 3-months and 4658110 shares per day over the past 10 days. A total of 256.14M shares are outstanding, with a floating share count of 247.13M. Insiders hold about 18.58% of the company’s shares, while institutions hold 68.16% stake in the company. Shares short for IOVA as of 1726185600 were 60293439 with a Short Ratio of 8.98, compared to 1723680000 on 59334386. Therefore, it implies a Short% of Shares Outstanding of 60293439 and a Short% of Float of 21.97.
